AKEURA

Fact Sheet

Cardiometabolic diseases rarely exist in isolation. Neither does our expertise.

One CRO across the cardiometabolic continuum

Obesity, diabetes, cardiovascular disease, chronic kidney disease, and MASH share biology, patients, and development challenges. AKEURA brings scientific leadership, patient access, and global delivery to studies across that continuum, from early phase through real-world evidence.

Selected cardiometabolic and renal experience

	Indication	Phase/Study Type	Location	Sites	Participants
ONGOING	Observational MASLD/MASH diagnostic study in high-risk populations	Observational	Europe	12	10,000
	RWE study of myocarditis natural history, outcomes, and risk factors	RWE	Europe	4	Database of more than 39 million
	Pragmatic trial of high-dose hemodiafiltration in end-stage kidney disease	Pragmatic	Europe	61	1,638
ONGOING	Phase III pivotal study in pediatric participants with a lipid disorder	Phase III	Europe, America, Asia-Pacific	160	170
ONGOING	Effects of drug combo on plaque regression and stabilization of coronary atherosclerosis	Phase IIIb	Europe	12	97
ONGOING	An open-label, multicenter, pivotal efficacy and safety study evaluating a device for glycemic improvement in participants with obesity and inadequately controlled type 2 diabetes on oral anti-diabetes agents	Phase II	America	20	67

Scientific leadership on every program

Our in-house cardiometabolic experts



Manuel Castro Cabezas, MD, PhD

Scientific Officer at AKEURA

An internist-endocrinologist, vascular medicine specialist, and Associate Professor of Endocrinology at Erasmus MC, Dr. Castro Cabezas brings expertise across diabetes, obesity, lipid disorders, vascular medicine, and steatotic liver disease. He is the founder of a thyroid network and leads the GRIPonMASH™ initiative, supporting earlier identification and referral of people at risk for metabolic liver disease.



Diederick “Rick” Grobbee, MD, PhD

Chief Scientific Officer at AKEURA

A Professor of Clinical Epidemiology at University Medical Center Utrecht, Prof. Grobbee has extensive experience designing and leading large-scale global trials in cardiovascular and cardiometabolic disease. He is Honorary President of the European Association of Preventive Cardiology and an internationally recognized leader in cardiovascular epidemiology and clinical research.

When trials stall, we get them moving.

CLEAR Outcomes CVOT

The Need: Speed up a trial already underway

The Challenge

Increase recruitment and site productivity after study launch by another CRO, while protecting retention and data quality.

Our Role

We supported 224 sites across Europe and the Americas, using targeted site communications, KOL engagement, CRA outreach, and performance analytics.

Results

- Recruited as many participants in the first year as the incumbent CRO, using approximately half the sites
- 1,667 participants across 224 sites
- 35% screen-failure rate, compared with 41% overall
- 0% lost to follow-up

SPIRE CVOT

The Need: Rescue global recruitment

The Challenge

Restore recruitment momentum across a large site network spanning 26 countries in Europe, the Americas, and Asia-Pacific.

Our Role

Working alongside another CRO, we provided full-service study support within the sponsor's and partner CRO's systems, driving site activation and enrollment across multiple therapeutic specialties.

Results

- Average 56 days from site initiation to first randomization
- 6,729 participants enrolled
- 757 sites successfully randomized participants, averaging 1.1 participants per site per month versus 0.7 across overall study

Broader access. Better-informed studies. Faster execution.

Scientific expertise, investigator relationships, and care networks, connected. That's how we sharpen feasibility, speed recruitment, and activate sites that perform.

Capability	Benefit
Integrated cardiometabolic expertise	**More informed feasibility, protocol design, and endpoint strategy**
Primary-care and specialist referral networks	**Broader patient access and earlier participant identification**
Global cardiometabolic investigator relationships	**Faster site identification, startup, and enrollment**
Longitudinal and real-world data capabilities	**Deeper insight into disease progression and treatment patterns**
Dedicated scientific leadership	**Strategic guidance and trusted peer-to-peer relationships throughout development**
Global operational delivery	**Exceptional execution across countries, sites, and partners**

Eva van Doorn
Head of Project Strategy and Delivery
eva.vandoorn@akeura.com

Bronwyn Secourgeon
Associate VP, Global Head of Cardiometabolic Diseases
bronwyn.secourgeon@akeura.com

Bridget Smith
Senior Director, Business Development
bridget.smith@akeura.com